6 active trials 0 recruiting 2 disease areas 4 changes in 30 days
1 trial changed in the last 30 days: 0 stopped, 0 with notable changes, 1 with a minor change only.
Enrollment closed, study ongoing
Also in this update: Primary and study completion pushed from Sep 11, 2026 to Feb 26, 2027; Trial sites expanded: 25 → 29 locations
NS Pharma, Inc.Phase 2 NCT05996003 Registry history of NCT05996003 on ClinicalTrials.gov (opens the registry)
Updated
| Phase 1/2 | 1 | |
| Phase 2 | 4 | |
| Phase 4 | 1 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT04687020 | Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical… | Duchenne Muscular Dystrophy | Active, Not Recruiting | 2022-10-19 |
| Phase 2 | ||||
| NCT05996003 | NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD) | Duchenne Muscular Dystrophy | Active, Not Recruiting | 2026-09-15 |
| NCT06046222 | Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic… | Eosinophilic Granulomatosis With Polyangiitis | Active, Not Recruiting | 2026-05-26 |
| NCT07441200 | Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension | Not Yet Recruiting | 2026-02-27 |
| NCT07441278 | A Clinical Trial of NS-863 in Participants With Pulmonary Hypertension Associated With… | Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) | Not Yet Recruiting | 2026-02-27 |
| Phase 1/2 | ||||
| NCT06053814 | NS-050/NCNP-03 in Boys With DMD (Meteor50) | Duchenne Muscular Dystrophy | Active, Not Recruiting | 2026-06-16 |
Duchenne Muscular Dystrophy (3) · Hypertension (2)